+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hunter Syndrome Treatment Market by Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration (Intravenous, Oral, Subcutaneous), Patient Age Group, End User - Global Forecast 2025-2030- Product Image
Hunter Syndrome Treatment Market by Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration (Intravenous, Oral, Subcutaneous), Patient Age Group, End User - Global Forecast 2025-2030- Product Image
Sale

Hunter Syndrome Treatment Market by Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration (Intravenous, Oral, Subcutaneous), Patient Age Group, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532898
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hunter Syndrome Treatment Market presents a complex and evolving environment, with active advancements in clinical innovation, regulatory adaptation, and global supply chain strategies shaping the industry’s direction for senior executives and stakeholders.

Market Snapshot: Hunter Syndrome Treatment Market Growth Prospects

The Hunter Syndrome Treatment Market grew from USD 1.17 billion in 2024 to USD 1.27 billion in 2025 and is projected to continue expanding at a CAGR of 8.15%, reaching USD 1.88 billion by 2030. Market development is fueled by next-generation gene therapies, continued enzyme replacement innovations, and strengthening policy incentives across global regions. Leading pharmaceutical and biotechnology companies are contributing to a dynamic pipeline, with late-stage clinical initiatives indicating expanded future access and improved patient outcomes.

Scope & Segmentation Overview

Detailed segmentation enables decisive planning and opportunity targeting for industry leaders:

  • Treatment Types: Enzyme replacement therapies (including idursulfase and idursulfase beta), gene therapies delivered by adeno-associated viral and lentiviral vectors, hematopoietic stem cell transplantation (both allogeneic and autologous), and supportive therapies focusing on nutritional, pain, physical, and respiratory management.
  • Routes of Administration: Intravenous, oral, and subcutaneous options tailored to therapeutic profile and patient needs.
  • Patient Demographics: Adult segments (young adult, middle-aged, senior) and pediatric cohorts (infant, toddler, child, adolescent), each requiring distinct care strategies.
  • End-User Channels: Hospitals, ambulatory surgical centers, home infusion programs, and specialty clinics help drive distribution and patient access through varied operational models.
  • Regional Coverage: Americas (United States with major states; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (ranging from established Western markets to emerging Middle Eastern and African regions), and Asia-Pacific (including rapid-growth markets such as Japan, China, South Korea, India, Australia, Indonesia, and others).
  • Company Coverage: Notable players analyzed include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Abbott, Denali Therapeutics, Medtronic, Johnson & Johnson Services, Inc., GSK Plc., Bayer AG, Zimmer Biomet, and Stryker Corporation.

Key Takeaways for Senior Decision-Makers

  • Ongoing advances in gene editing and personalized medicine are enabling durable disease modification, moving beyond traditional symptomatic management and offering potential improvements in quality of life.
  • Regulatory bodies show increased flexibility through expedited approvals and orphan drug incentives, creating faster pathways from R&D to commercialization and enabling rapid access to transformative therapies.
  • Regional market entry demands tailored approaches, as infrastructure maturity, reimbursement strategies, and regulatory readiness differ widely across global markets, especially between mature and emerging geographies.
  • Collaboration models among pharma, technology, and research organizations are strengthening, optimizing supply chains and supporting the development of digital health tools for patient monitoring and adherence tracking.
  • Innovative commercial strategies—emphasizing value-based contracting and outcome-driven agreements—are key to securing favorable reimbursement and ensuring sustainable market access for high-cost therapies.

Tariff Impact: 2025 U.S. Changes and Global Supply Chains

Recent United States tariffs have added complexity to the Hunter syndrome treatment supply chain. Tariff increases on biologic components and specialized inputs prompt biopharmaceutical manufacturers to reevaluate sourcing, regionalize production, and renegotiate supply agreements. These shifts drive up-front costs and require new procurement and margin management approaches. Providers and payers are now compelled to consider tariffs in reimbursement models and pricing negotiations, with proactive organizations best positioned to maintain supply chain resilience, financial sustainability, and uninterrupted patient care.

Methodology & Data Sources

This research uses a multi-tiered framework, blending primary interviews with industry experts, clinical leaders, payers, and advocacy groups, alongside secondary data from peer-reviewed journals, regulatory filings, and proprietary market intelligence sources. Quantitative triangulation and scenario modeling underpin the findings, ensuring robust validation across regulatory, technological, and market variables.

Why This Report Matters

  • Enables strategic planning by mapping the evolving competitive landscape, segment trends, and market access drivers for senior leaders in biopharma, healthcare, and investment sectors.
  • Supports operational decision-making through actionable insights on technology adoption, regulatory shifts, and supply chain optimization in rare disease therapeutics.
  • Helps quantify and evaluate emerging risks and opportunities in a rapidly changing global environment, especially relevant for organizations pursuing innovation and long-term market positioning.

Conclusion

In summary, this report delivers comprehensive, actionable intelligence for stakeholders navigating the future of Hunter syndrome treatments. Supported by expert-driven analysis, it illuminates opportunity, risk, and requirement in a transforming therapeutic marketplace.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in gene therapy targeting iduronate-2-sulfatase gene correction in vivo for Hunter syndrome patients
5.2. Expansion of newborn screening programs for early detection of mucopolysaccharidosis II to improve treatment outcomes
5.3. Development and phase III clinical trial outcomes of novel enzyme replacement therapies with enhanced blood-brain barrier penetration
5.4. Regulatory approvals and global market access strategies for intrathecal idursulfase formulations addressing neurological symptoms
5.5. Emergence of small-molecule pharmacological chaperones to stabilize mutant iduronate-2-sulfatase and reduce substrate accumulation
5.6. Patient adherence initiatives and cost-effectiveness analyses of extended-interval enzyme replacement therapy infusions
5.7. Real-world evidence on quality-of-life improvements with combined gene therapy and enzyme replacement approaches in pediatric patients
5.8. Collaborative research programs exploring CRISPR-based ex vivo correction of IDS mutations in hematopoietic stem cells for long-term treatment
5.9. Shifts in payer reimbursement models and health technology assessments for high-cost Hunter syndrome therapies impacting patient access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hunter Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Enzyme Replacement Therapy
8.2.1. Idursulfase
8.2.2. Idursulfase Beta
8.3. Gene Therapy
8.3.1. Adeno Associated Virus Vector
8.3.2. Lentiviral Vector
8.4. Hematopoietic Stem Cell Transplant
8.4.1. Allogeneic Transplant
8.4.2. Autologous Transplant
8.5. Supportive Therapy
8.5.1. Nutritional Support
8.5.2. Pain Management
8.5.3. Physical Therapy
8.5.4. Respiratory Support
9. Hunter Syndrome Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Hunter Syndrome Treatment Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.2.1. Middle Aged
10.2.2. Senior
10.2.3. Young Adult
10.3. Pediatric
10.3.1. Adolescent
10.3.2. Child
10.3.3. Infant
10.3.4. Toddler
11. Hunter Syndrome Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Home Infusion
11.4. Hospital
11.5. Specialty Clinic
12. Americas Hunter Syndrome Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Hunter Syndrome Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Hunter Syndrome Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Takeda Pharmaceutical Company Limited
15.3.2. F. Hoffmann-La Roche Ltd
15.3.3. Abbott
15.3.4. Denali Therapeutics
15.3.5. Medtronic
15.3.6. Johnson & Johnson Services, Inc.
15.3.7. GSK Plc.
15.3.8. Bayer AG
15.3.9. Zimmer Biomet
15.3.10. Stryker Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HUNTER SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. HUNTER SYNDROME TREATMENT MARKET: RESEARCHAI
FIGURE 24. HUNTER SYNDROME TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 25. HUNTER SYNDROME TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 26. HUNTER SYNDROME TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUNTER SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 133. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 140. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 141. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 142. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 143. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 146. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 147. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 148. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 149. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 150. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 151. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 156. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 157. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 160. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 161. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 162. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 163. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 168. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 169. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 170. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 171. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 258. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 259. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 260. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 261. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 262. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 263. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 264. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 265. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 268. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 269. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 270. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 271. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 272. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 273. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 278. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 279. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 280. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 281. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 282. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 283. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 284. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 285. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 288. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 289. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 290. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 291. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 292. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 293. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (U

Samples

Loading
LOADING...

Companies Mentioned

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • Denali Therapeutics
  • Medtronic
  • Johnson & Johnson Services, Inc.
  • GSK Plc.
  • Bayer AG
  • Zimmer Biomet
  • Stryker Corporation

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.88 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report by Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration, End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report by Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), Route Of Administration, End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Hunter Syndrome Treatment - Global Strategic Business Report - Product Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Hunter Syndrome Treatment Market Report and Forecast 2024-2032 - Product Image

Hunter Syndrome Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Lysosomal Storage Diseases Market by Disease Type (Fabry Disease, Gaucher Disease, Hunter Syndrome), Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant), Therapeutic Application, End-User - Global Forecast 2025-2030 - Product Image

Lysosomal Storage Diseases Market by Disease Type (Fabry Disease, Gaucher Disease, Hunter Syndrome), Treatment Type (Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplant), Therapeutic Application, End-User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From

About the Mucopolysaccharidosis Drug Market

Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the deficiency of lysosomal enzymes. These enzymes are responsible for breaking down complex sugars called glycosaminoglycans (GAGs). Without these enzymes, GAGs accumulate in the body, leading to a wide range of symptoms, including skeletal deformities, organ enlargement, and cognitive impairment. Treatment for MPS is focused on managing symptoms and preventing further progression of the disease. Immune disorders drugs are used to treat MPS, including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy. ERT involves the administration of a recombinant enzyme to replace the missing enzyme, while SRT works by reducing the production of GAGs. Gene therapy is a newer approach that involves the introduction of a healthy gene into the patient's cells to replace the defective gene. Companies in the MPS drug market include Sanofi, Shire, Pfizer, and Ultragenyx Pharmaceuticals. Sanofi is a French pharmaceutical company that produces Aldurazyme, an ERT drug for MPS I. Shire is a biopharmaceutical company that produces Elaprase, an ERT drug for MPS II. Pfizer is an American pharmaceutical company that produces Vimizim, an ERT drug for MPS IV. Ultragenyx Pharmaceuticals is a biopharmaceutical company that produces Mep Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.